potent
effect
antivir
drug
recent
licens
sever
viral
diseas
usher
new
era
treatment
viral
diseas
time
seen
widespread
adopt
rapid
diagnost
test
identifi
specif
viral
etiolog
develop
bring
us
point
diagnosi
effect
treatment
mani
viral
diseas
commonplac
sever
antivir
agent
target
examin
review
acyclovir
effect
herp
simplex
viru
varicella
zoster
viru
ribavirin
recent
introduc
effect
respiratori
syncyti
viru
amantadin
effect
influenza
type
virus
anticytomegaloviru
agent
antihuman
immunodefici
viru
agent
immunomodul
interferon
investig
older
agent
adenosin
arabinosid
idoxuridin
replac
newer
effect
agent
taken
us
long
time
reach
point
render
viru
inact
formid
feat
kill
bacteria
bacteria
reproduc
outsid
human
cell
sever
uniqu
featur
distinguish
human
cell
virus
contrast
reproduc
within
human
cell
fewer
uniqu
featur
select
inhibit
recent
year
sever
uniqu
featur
process
viral
infect
identifi
target
point
interfer
inhibit
uniqu
step
process
interf
compound
subject
review
acyclovir
zovirax
current
effect
agent
sever
herpesvirus
synthet
acycl
purin
guanosin
nucleosid
ana
logu
without
cyclic
sugar
moieti
natur
nucleosid
natur
occur
nucleosid
compos
five
carbon
sugar
attach
base
singl
ring
thymidin
deoxycytidin
doubl
ring
deoxyguanosin
deoxyadenosin
nucleosid
analogu
differ
natur
one
chang
sugar
base
moieti
fig
phosphat
attach
nucleosid
form
nucleotid
nucleosid
analogu
interrupt
replic
grow
nucleic
acid
chain
interf
phosphoryl
enzym
bind
mechan
acyclovir
acv
antivir
activ
certain
member
herpesviru
famili
herp
simplex
type
varicella
zoster
viru
epsteinbarr
viru
cytomegaloviru
mechan
action
acv
inhibit
viral
dna
polymeras
util
infect
cell
virusspecif
thymidin
kinas
drug
enter
infect
cell
viral
thymidin
kinas
phosphoryl
acv
monophosph
deriv
drug
phosphoryl
host
cell
enzym
triphosph
deriv
inhibit
viral
dna
polymeras
triphosph
compound
select
inhibit
viral
dna
polymeras
compet
host
guanosin
triphosph
substrat
enzym
dna
chain
elong
replic
therebi
inhibit
fig
triphosph
compound
potent
inhibitor
viral
dna
polymeras
cellular
dna
polymeras
make
phosphoryl
acv
highli
specif
agent
herp
infect
cell
acv
bind
time
avidli
viral
thymidin
kinas
cellular
thymidin
kinas
addit
acv
phosphoryl
rapidli
viral
thymidin
kinas
cellular
thymidin
kinas
amount
acv
triphosph
compound
gener
infect
cell
time
normal
cell
second
mechan
action
acv
recogn
explain
drug
activ
epsteinbarr
viru
ebv
ebv
viral
specif
thymidin
kinas
acv
phosphoryl
avidli
rapidli
ebv
infect
cell
instead
drug
appear
direct
action
ebv
viral
dna
polymeras
pharmacokinet
acyclovir
excret
kidney
halflif
total
bodi
clearanc
acv
depend
renal
function
patient
normal
renal
function
halflif
hour
neonat
slightli
longer
hour
anur
patient
increas
hour
infus
mg
per
kg
per
hour
peak
plasma
concentr
averag
flg
per
ml
trough
level
flg
per
ml
mg
per
kg
per
hour
peak
percutan
absorpt
acv
poor
renal
excret
acv
glomerular
filtrat
renal
tubular
secret
kidney
excret
mostli
unmetabol
acyclovir
less
per
cent
excret
metabolit
tubular
secret
account
per
cent
administ
dose
dosag
reduct
recommend
patient
creatinin
clearanc
less
ml
per
minut
per
acv
easili
hemodialyz
routin
dialysi
per
cent
drug
remov
acv
may
reduc
renal
clearanc
drug
secret
kidney
methotrex
one
exampl
toxic
side
effect
contraind
use
acyclovir
except
patient
known
suspect
hypersensit
reaction
use
orallv
short
cours
common
advers
reaction
nausea
voit
headach
longer
cours
common
advers
reaction
headach
nausea
vomit
diarrhea
topic
appli
acv
may
caus
transient
burn
appli
genit
lesion
commonli
time
first
episod
often
femal
male
poli
ethylen
glycol
base
topic
acv
known
caus
erythema
appli
vagin
use
intravagin
applic
acv
given
intraven
usual
well
toler
although
local
irrit
infus
site
note
uncommon
side
effect
includ
rash
diaphoresi
hematuria
hypertens
headach
nausea
encephalopath
chang
note
per
cent
patient
chang
includ
lethargi
dull
tremor
confus
hallucin
delirium
seizur
coma
risk
factor
neurolog
symptom
includ
use
high
dose
intraven
mg
per
per
hour
simultan
administr
methotrex
interferon
seen
per
cent
bone
marrow
transplant
patient
resolut
symptom
occur
discontinu
drug
return
patient
put
back
drug
renal
dysfunct
note
patient
treat
intraven
acv
impair
renal
function
caus
crystal
format
renal
tubul
crystal
format
occur
plasma
concentr
high
immedi
follow
bolu
inject
slow
infus
acv
hour
good
hydrat
seem
prevent
crystalluria
addit
dehydr
highdos
rapid
infus
renal
insuffici
also
risk
factor
develop
crystalluria
particular
care
taken
acv
given
patient
aminoglycosid
cyclosporin
nephrotox
agent
acv
also
associ
abnorm
hepat
function
bone
marrow
depress
immunocompromis
patient
drug
teratogen
mutagen
use
pregnanc
without
fear
injuri
fetu
fact
treatment
sever
herp
infect
may
prevent
placent
transmiss
infect
report
drug
resist
herp
simplex
viru
patient
treat
lack
clinic
respons
resist
yet
report
indic
acyclovir
use
topic
oral
intraven
varieti
type
herpet
infect
genit
herp
simplex
infect
initi
treat
topic
acv
durat
viral
shed
significantli
reduc
topic
acv
effect
reduc
time
crust
time
heal
develop
new
lesion
constitut
symptom
pain
addit
mild
transient
burn
pain
associ
topic
applic
recent
shown
poor
clinic
respons
due
failur
topic
acyclovir
polyethylen
glycol
base
penetr
skin
treatment
oral
acv
replac
topic
acyclovir
treatment
choic
genit
herp
infect
use
oral
acv
shorten
mean
durat
viral
shed
time
crust
time
heal
durat
local
pain
constitut
symptom
acv
given
intraven
sever
primari
genit
herp
simplex
infect
substanti
decreas
symptom
durat
lesion
complic
treatment
oral
acv
success
recurr
genit
herp
acv
therapi
institut
within
hour
appear
lesion
durat
viral
shed
shorten
heal
faster
situat
patient
start
therapi
soon
possibl
appear
new
lesion
similar
chang
time
crust
heal
durat
viral
shed
addit
fewer
new
lesion
form
oral
acv
also
suppress
recurr
herp
simplex
infect
recurr
lesion
appear
significantli
fewer
number
untreat
case
therapi
well
toler
longterm
use
month
suppress
therapi
resist
strain
found
longterm
suppress
therapi
acv
may
result
develop
drug
resist
resist
isol
far
come
immunocompromis
patient
receiv
multipl
cours
therapi
activ
infect
resist
strain
typic
defici
thymidin
kinas
length
therapi
suppress
adequ
defin
longterm
side
effect
toxic
studi
acv
use
suppress
therapi
sever
year
current
recommend
treat
patient
month
suppress
recurr
genit
herp
infect
chronic
suppress
therapi
cost
effect
patient
six
recurr
per
year
therapi
also
indic
patient
experi
seriou
complic
recurr
erythema
multiform
asept
mening
eczema
herpeticum
chronic
suppress
therapi
stop
month
determin
whether
frequenc
recurr
chang
rate
decreas
significantli
chronic
prophylaxi
may
stop
clinic
trial
current
progress
evalu
efbcaci
safeti
suppress
therapi
month
recurr
acvtreat
patient
less
frequent
shorter
durat
placebo
group
similar
result
shown
smaller
trial
drug
discontinu
howev
recurr
return
pretreat
frequenc
patient
report
unusu
sever
symptom
first
posttreat
recurr
resist
strain
herp
respons
breakthrough
recurr
acv
use
immunocompromis
patient
treat
well
suppress
mucocutan
herp
simplex
infect
oral
acv
effect
intraven
acv
treat
infect
suppress
therapi
use
success
long
month
occurr
develop
cessat
therapi
safeti
beyond
month
use
drug
unknown
investig
recent
recommend
broaden
prophylact
use
acv
immunocompromis
host
patient
undergo
bone
marrow
transplant
induct
chemotherapi
hematolog
malign
routin
screen
herp
antibodi
perform
seroposit
patient
given
acv
begin
day
condit
induct
continu
approxim
week
investig
stop
acv
absolut
granulocyt
count
marrow
engraft
success
similar
recommend
may
appropri
cardiac
renal
liver
transplant
patient
patient
acquir
immunodefici
syndrom
aid
although
dose
vari
depend
clinic
set
acv
use
intraven
current
treatment
choic
herp
simplex
enceph
recommend
dosag
mg
per
kg
per
hour
compar
vidarabin
therapi
intraven
acv
show
lower
morbid
mortal
acv
also
use
normal
host
mucocutan
herp
infect
herpet
whitlow
acv
effect
control
certain
manifest
varicella
zoster
viru
immunocompromis
immunocompet
host
commonli
use
immunocompromis
patient
herp
zoster
dissemin
use
local
zoster
prevent
dissemin
patient
acyclovir
administ
intraven
dose
mg
per
kg
per
hour
acv
shown
effect
agent
varicella
zoster
infect
immunocompet
host
local
zoster
rash
dissemin
diseas
acv
prevent
progress
dissemin
enhanc
thc
rate
clearanc
provid
faster
relief
pain
placebo
intraven
acv
use
outpati
set
treat
herpc
zoster
higher
frequenc
advers
reaction
seen
possibl
due
poorer
hydrat
state
vivo
resist
found
treat
varicella
zoster
casc
recent
report
herp
zosterassoci
enceph
respond
rapidli
intraven
acv
mg
per
kg
per
day
within
hour
resolut
encephalopathi
normal
electroencephalogramj
j
use
acv
extend
herp
viru
infect
beyond
herp
varicella
zoster
virus
epsteinbarr
viru
ebv
infect
sever
acut
infecti
mononucleosi
particular
treat
acv
signific
effect
drug
acut
mononucleosi
inhibit
oropharyng
shed
ebv
affect
humor
cellular
immun
respons
affect
viral
latenc
moreov
clinic
symptom
fever
weight
loss
pharyng
sens
wellb
significantli
better
examin
individu
clinic
find
combin
signific
posit
effect
seen
acv
treatment
compar
placebo
treatment
sever
chronic
ebv
infect
associ
fever
interstiti
pneumon
seem
respond
intraven
use
acv
treatment
sezari
syndrom
mycosi
fungoid
recent
report
diseas
group
togeth
cutan
cell
lymphoma
evid
may
caus
viral
infect
unlik
acv
anoth
nucleosid
analogu
activ
herp
virus
ribavirin
broad
spectrum
activ
deriv
ribofuranosin
close
resembl
guanosin
inosin
see
fig
poorli
understood
sever
differ
mechan
postul
decreas
intracellular
concentr
guanosin
triphosph
caus
competit
inhibit
inosin
monophosph
dehydrogenas
inhibit
cap
format
messeng
rna
mrna
inhibit
function
viru
code
rna
polymeras
necessari
prime
elong
viral
rna
appear
interfer
attach
penetr
viru
cell
induc
interferon
incorpor
whole
cell
rna
dna
virus
inhibitori
activ
three
major
human
dna
viral
group
adenovirus
herpesvirus
poxvirus
rna
virus
inhibit
includ
respiratori
virus
influenza
type
b
respiratori
syncyti
viru
rsv
parainfluenza
virus
measl
arenaviru
bunyaviru
also
sensit
ribavirin
anim
model
enterovirus
appear
sensit
ribavirin
cross
bloodbrain
barrier
well
effect
viral
encephalitid
pharmacokinet
ribavirin
administ
aerosol
mouth
inhal
ribavirin
low
concentr
appear
system
circul
concentr
respiratori
secret
time
higher
given
oral
thu
areosol
administr
result
extraordinarili
high
level
respiratori
secret
littl
system
absorpt
ribavirin
accumul
blood
administ
aerosol
length
therapi
greater
hour
peak
level
increas
subsequ
day
treatment
hour
administr
mean
peak
plasma
level
flg
per
ml
mean
peak
level
respiratori
secret
flg
per
ml
hi
minim
inhibitori
concentr
rsv
rang
flg
per
ml
halflif
ribavirin
plasma
hour
respiratori
secret
hour
metabol
ribavirin
incomplet
understood
either
oral
intraven
administr
ribavirin
accumul
red
blood
cell
may
persist
week
cessat
therapi
oral
administr
halflif
red
blood
cell
day
compar
hour
urin
long
halflif
red
blood
cell
caus
phosphoryl
ribavirin
ribavirin
triphosph
rtp
red
cell
cell
inabl
dephosphoryl
rtp
ribavirin
appear
urin
metabol
form
toxic
advers
reaction
littl
toxic
ribavirin
administ
aerosol
well
toler
signific
advers
effect
report
although
rash
conjunct
occur
report
lung
damag
acut
use
aerosol
effect
oflongterm
use
develop
lung
adequ
studi
howev
ribavirin
use
patient
mechan
ventil
result
malfunct
respir
caus
precipit
drug
valv
tube
aerosol
drug
therefor
use
patient
respir
oral
intraven
use
transient
normochrom
normocyt
anemia
becn
report
anemia
dosedepend
caus
rapid
extravascular
clear
red
blood
cell
higher
dose
suppress
red
blood
cell
line
bone
marrow
occur
earli
studi
use
oral
ribavirin
show
elev
bilirubin
level
may
reflect
rapid
clearanc
red
blood
cell
monkey
rat
studi
ribavirin
mutagen
teratogen
embryotox
possibl
carcinogen
clinic
use
ribavirin
use
therapeut
around
world
fcx
varieti
viral
infect
includ
rsv
influenza
type
b
lassa
fever
junin
viru
machupo
viru
ribavirin
commerci
avail
unit
state
treat
rsv
infant
deliv
almost
continu
basi
via
aerosol
rout
demonstr
ribavirin
therapi
improv
arteri
blood
gase
decreas
amount
viral
shed
nasal
wash
toxic
observ
ribavirin
effect
agent
influenza
given
aerosol
rout
aerosol
ribavirin
begun
within
hour
onset
flulik
symptom
decreas
viral
shed
fever
system
symptom
caus
influenza
type
set
ribavirin
given
hour
almost
continu
day
day
use
oral
ribavirin
yield
mix
result
shown
effect
treatment
lassa
fever
result
infect
arenaviru
mortal
lassa
fever
directli
relat
two
risk
factor
high
level
aspart
aminotransferas
viremia
patient
group
one
risk
factor
treat
oral
intraven
ribavirin
mortal
reduc
per
cent
compar
group
treat
lassa
fever
immun
plasma
ribavirin
shown
effect
anim
model
infect
junin
viru
agent
argentin
hemorrhag
fever
machupo
viru
agent
bolivian
hemorrhag
fever
ribavirin
decreas
viremia
increas
surviv
although
anim
ultim
die
subsequ
enceph
final
anim
ribavirin
shown
inhibit
growth
vesicular
stomat
viru
dose
administr
ribavirin
deliv
oxygen
mask
small
particl
aerosol
drug
administ
mean
specif
small
particl
collison
gener
produc
aerosol
median
particl
size
mm
concentr
ribavirin
reservoir
mg
per
ml
dose
ribavirin
deliv
estim
mg
per
kg
per
hour
administr
aerosol
administr
manner
result
high
level
respiratori
secret
littl
system
absorpt
rsv
influenza
infect
ribavirin
given
continu
hour
per
day
except
meal
given
least
day
highest
concentr
obtain
administr
via
endotrach
tube
rather
oxygen
hood
mask
tent
collison
gener
suppli
icn
pharmaceut
manufactur
ribavirin
virazol
lassa
fever
ribavirin
given
oral
g
load
dose
follow
g
per
day
divid
dose
everi
hour
day
intraven
ribavirin
also
use
lassa
fever
given
g
load
dose
follow
g
dose
everi
hour
day
everi
hour
day
vidarabin
araa
vi
raa
adenin
arabinosid
one
first
effect
antiherpesviru
drug
avail
intraven
use
human
vidarabin
analogu
deoxyadenosin
adenin
deoxyribosid
see
fig
also
dna
synthesi
inhibitor
spectrum
vidarabin
vitro
activ
herp
simplex
virus
type
varicella
zoster
viru
ebv
vaccinia
variola
rhabdovirus
rna
tumor
virus
activ
cytomegaloviru
cmv
variabl
vitro
inhibit
replic
acvresist
herp
strain
acvresist
varicella
zoster
idoxuridineresist
herp
strain
lo
mechan
action
cellular
enzym
convert
adenin
arabinosid
vidarabin
adenin
arabinosid
triphosph
directli
inhibit
dna
polymeras
herp
simplex
viru
also
may
act
substrat
incorpor
herp
viru
dna
fig
triphosph
compound
act
chain
termin
newli
synthes
herp
simplex
dna
primari
metabolit
hypoxanthin
arabinosid
arahx
time
less
activ
arahx
howev
seem
enhanc
activ
araa
araa
also
inhibit
sadenosylhomocystein
hydrolas
vitro
red
blood
cell
patient
treat
araa
sadenosylhomocystein
hydrolas
enzym
involv
transmethyl
effect
araa
enzym
persist
cessat
therapi
may
explain
toxic
araa
pharmacokinet
vidarabin
rel
insolubl
water
administ
intraven
larg
volum
fluid
slow
infus
follow
infus
vidarabin
rapidli
metabol
adenosin
deaminas
arahx
plasma
level
peak
flg
per
ml
almost
detect
level
vidarabin
arahx
cross
bloodbrain
barrier
present
cerebrospin
fluid
per
cent
plasma
concentr
vidarabin
renal
clear
per
cent
arahx
per
cent
vidarabin
serum
halflif
hour
adult
vidarabin
detect
red
blood
cell
week
end
therapi
renal
insuffici
plasma
arahx
concentr
elev
may
increas
risk
toxic
per
cent
reduct
dosag
recommend
sever
renal
insuffici
vidarabin
remov
hemodialysi
toxic
advers
reaction
major
side
effect
vidarabin
nausea
vomit
diarrhea
anorexia
weight
loss
poor
solubl
drug
must
administ
l
fluid
daili
dosag
mg
per
kg
per
day
convent
dose
liver
renal
bone
marrow
toxic
seen
dosag
mg
per
kg
per
day
megaloblast
bone
marrow
chang
anemia
leukopenia
thrombocytopenia
report
infusionrel
thrombophleb
weak
rash
hypokalemia
inappropri
antidiuret
hormon
syndrom
also
report
neurotox
describ
includ
pain
syndrom
extrem
last
month
cessat
therapi
intent
tremor
grimac
myoclonu
ataxia
mood
behavior
chang
dysgraphia
disorient
aphasia
depress
mutism
agit
hallucin
also
seen
coma
seizur
rare
high
dosag
preexist
hepat
renal
failur
predispos
risk
factor
concomit
use
interferon
allopurinol
increas
risk
toxic
serum
concentr
arahx
found
higher
toxic
patient
drug
teratogen
carcinogen
mutagen
certain
anim
clinic
indic
vidarabin
initi
use
treat
herpesviru
infect
especi
herp
simplex
enceph
also
effect
treat
neonat
herp
simplex
varicella
zoster
herp
simplex
kerat
vidarabin
shown
reduc
mortal
herp
simplex
enceph
biopsi
proven
patient
recent
studi
howev
confirm
acv
drug
choic
diseas
vidarabin
limit
therapeut
use
mucocutan
herp
simplex
infect
immunocompromis
patient
therefor
larg
replac
acv
treatment
infect
vidarabin
also
use
patient
chronic
hepat
b
infect
hepat
b
viru
specif
dna
polymeras
well
hbsag
hbeag
titer
reduc
treat
patient
greater
benefit
occur
interfcron
ad
vidarabin
therapi
f
treatment
chronic
hcpatiti
dosag
herp
simplex
enceph
rangc
mg
per
kg
pcr
day
averag
mg
per
kg
per
day
day
vidarabin
monophosph
adenin
arabinosid
imonophosph
araamp
viraamp
new
form
vidarabinc
undergo
clinic
test
major
advantag
given
intramuscularli
requir
larg
volum
fluid
given
intraven
solubl
araa
intramuscular
form
may
advantag
ambulatori
therapi
patient
varicella
zoster
infect
dhpg
guanin
antivir
purin
analogu
acycl
nucleosid
structur
relat
acv
cmv
also
activ
dna
virus
vaccinia
adenoviru
inact
rna
virus
specif
thymidin
kinas
cmv
infect
cell
dhpg
phosphoryl
monophosph
deriv
cellular
deoxyguanosin
kinas
phosphoryl
triphosph
phosphoryl
time
readili
infect
cell
dhpgtriphosph
competit
inhibit
bind
deoxyguanosin
triphosph
dna
polymeras
thu
inhibit
dna
synthesi
termin
dna
elong
poor
renal
function
increas
hour
drug
level
lung
liver
averag
per
cent
per
cent
blood
level
respect
dhpg
penetr
central
nervou
system
per
cent
blood
level
publish
studi
mean
peak
plasma
level
exceed
mean
inhibitori
dose
excret
per
cent
unchang
urin
within
hour
toxic
advers
effect
advers
effect
often
doserel
includ
inhibit
spermatogenesi
bone
marrow
depress
obstruct
nephropathi
atrophi
necrosi
gastrointestin
mucosa
bone
marrow
effect
includ
leukopenia
thrombocytopenia
eosinophilia
report
well
gastrointestin
reaction
includ
nausea
anorexia
vomit
increas
liver
enzym
one
report
patient
develop
edema
disorient
also
report
clinic
indic
dhpg
write
commerci
avail
promis
anticmv
agent
publish
report
use
cmv
infect
transplant
patient
aid
patient
immunocompromis
patient
heal
retin
lesion
resolut
viremia
viru
shed
seen
use
dhpg
treat
cmv
retin
drug
discontinu
howev
deterior
vision
occur
new
hemorrhag
seen
retina
aid
patient
mainten
therapi
appear
necessari
prevent
reoccurr
j
revers
retin
seen
dhpg
often
treatment
stabil
arrest
furthcr
progress
retin
damag
anim
studic
comparison
acv
dhpg
therapi
civ
pncumon
show
dhpg
effect
acv
reduc
concentr
live
viru
lung
tissu
salivari
gland
drug
reduc
sever
pneumon
neither
abl
prevent
studi
cv
pneumon
transplant
patient
dhpg
therapi
suppress
viral
replic
cessat
viremia
viruria
addit
cmv
elimin
respiratori
secret
dhpg
promptli
revers
progress
infect
despit
good
vitro
vivo
antivir
effect
improv
surviv
occur
patient
relaps
cessat
therapi
dosag
intraven
mg
per
kg
per
day
three
divid
dose
given
hour
per
infus
dose
interv
adjust
accord
serum
creatinin
total
dose
reduc
presenc
neutropenia
side
effect
length
therapi
day
lainten
regimen
mg
per
kg
two
five
divid
dose
week
dhpg
still
experiment
therapi
dosag
yet
standard
oral
prepar
investig
mechan
action
amantadin
appear
inhibit
uncoat
viru
enter
cell
presenc
amantadin
viru
attach
normal
penetr
mammalian
cell
uncoat
viru
fail
occur
amantadin
also
appear
inhibit
initi
transcript
point
uncoat
viru
initi
viral
specif
rna
synthesi
pharmacokinet
amantadin
administ
oral
capsul
tablet
syrup
appear
peak
plasma
level
vari
wide
averag
hour
mg
dose
peak
plasma
concentr
averag
flg
per
ml
plasma
halflif
hour
halflif
increas
elderli
presenc
renal
insuffici
amantadin
excret
unmetabol
urin
glomerular
filtrat
tubular
secret
toxic
side
effect
oral
administ
amantadin
well
toler
without
seriou
renal
hepat
hematopoiet
toxic
amantadin
may
caus
mild
transient
central
nervou
system
reaction
insomnia
lightheaded
difficulti
concentr
neurotox
enhanc
simultan
use
anticholinerg
agent
antihistamin
may
gastrointestin
complaint
anorexia
nausea
reaction
relat
dose
durat
administr
reaction
associ
dose
mg
per
day
less
like
dose
mg
per
day
healthi
young
adult
clinic
indic
amantadin
use
prophylact
well
therapeut
influenza
use
effect
prevent
infect
subtyp
influenza
exampl
subtyp
recommend
prophylaxi
elderli
chronic
ill
receiv
vaccin
adjunct
late
immun
highrisk
individu
immunodefici
person
expect
show
poor
antibodi
respons
immun
healthi
person
care
highrisk
person
vaccin
contraind
therapi
influenza
infect
amantadin
reduc
durat
fever
symptom
per
cent
patient
treat
first
hour
ill
also
decreas
viral
shed
antibodi
respons
infect
diminish
amantadin
dosag
prophylaxi
mg
daili
taken
oral
start
soon
influenza
type
identifi
commun
continu
week
amantadin
also
start
concomitantli
influenza
vaccin
administr
continu
week
antibodi
respons
develop
therapeut
use
mg
per
day
begin
within
day
onset
symptom
continu
hour
resolut
ill
acetaminophen
given
simultan
bring
fever
salicyl
antipyret
use
elderli
patient
renal
failur
dose
reduc
mg
per
day
less
accord
recommend
us
public
health
servic
children
year
dose
mg
per
day
exceed
mg
rimantadin
rimantadin
structur
analogu
amantadin
spectrum
activ
mechan
action
clinic
indic
himantadin
current
investig
drug
plasma
halflif
approxim
hour
twice
amantadin
drug
exeret
urin
hydroxyl
metabolit
toxic
similar
amantadin
rimantadin
howev
increas
incid
gastrointestin
complaint
less
central
nervou
system
aid
caus
human
immunodefici
viru
hiv
formerli
htlv
illla
v
retroviru
hiv
requir
revers
transcriptas
fc
r
viral
replic
sever
agent
inhibit
revers
transcriptas
step
viral
replic
undergo
efficaci
studi
fig
suramin
oligonucleotid
rifamycin
includ
ansamycin
actinomycin
daunomycin
aractp
translat
inhibit
interferon
antisens
oligom
viral
assembl
affect
interferon
glycosyl
inhibitor
tunicamycin
inhibit
hud
viru
cell
membran
also
he
studi
agent
studi
extens
reviw
azt
nucleosid
analogu
thymidin
recent
licens
retrovir
zidovudin
mechan
action
termin
viral
dna
synthesi
azt
incorpor
viral
dna
hiy
revers
transcriptas
azido
group
n
replac
hydroxi
oh
group
thymidin
fig
azido
group
prevent
format
phosphodiest
linkag
therebi
termin
dna
synthesi
action
specif
revers
transcriptas
hiy
timc
activ
hiy
revers
transcriptas
mammalian
cell
dna
polymeras
pharmacokinet
azt
administcr
oral
intraven
metabol
liver
glucuronid
excret
kidney
halflif
approxim
hour
azt
appear
good
cercbrospin
fluid
penetr
bioavail
serum
per
cent
oral
dose
toxic
advers
reaction
bone
marrow
depress
major
advers
reaction
anemia
occur
per
cent
patient
take
azt
appear
doserel
granulocytopenia
thrombocytopenia
thrombocytosi
also
occur
patient
treat
year
without
experienc
myelosuppress
folat
vitamin
defici
may
enhancc
bone
narrow
suppress
ehect
azt
headach
agit
rcstless
insomnia
also
occur
azt
extens
studi
longterm
toxic
still
unknown
concomit
administr
cytotox
drug
addit
effect
bone
marrow
acetaminophen
use
concomitantli
increas
risk
granulocytopenia
drug
interfer
hepat
glucuronid
renal
excret
hepat
blood
flow
azt
probenecid
cimetidin
lorazepam
indomethacin
may
decreas
metabol
breakdown
excret
azt
increas
toxic
effect
clinic
trial
nineteen
hivposit
patient
aid
aid
relat
complex
arc
initi
treat
trial
azt
patient
given
mg
per
kg
intraven
everi
hour
day
follow
week
azt
use
mg
per
kg
per
day
oral
fifteen
patient
helpersuppressor
cell
ratio
improv
delay
hypersensit
skin
reaction
develop
six
patient
anerg
prior
therapi
eight
improv
clinic
infect
improv
dementia
neurolog
symptom
earli
aid
arc
patient
particip
doubleblind
placebocontrol
studi
oral
azt
studi
show
significantli
greater
mortal
placebo
group
azt
appear
decreas
mortal
improv
thelperlsuppressor
ratio
host
respons
opportunist
infect
oral
drug
recent
licens
data
current
avail
howev
suffici
definit
comment
benefitrisk
ratio
determin
group
hiv
infect
patient
benefit
receiv
azt
clinic
indic
drug
approv
certain
hiv
infect
adult
patient
histori
cytolog
confirm
pneumocysti
carinii
pneumonia
absolut
lymphocyt
count
less
per
mm
peripher
blood
therapi
begun
dosag
oral
mg
two
mg
capsul
everi
hour
kg
adult
dose
correspond
mg
per
kg
per
hour
anemia
granulocytopenia
develop
therapi
dose
reduc
mg
everi
hour
discontinu
consult
drug
packag
insert
detail
intraven
mg
per
kg
everi
hour
lower
dose
anemia
develop
requir
length
therapi
unknown
oral
ribavirin
use
patient
aid
aidsrel
complex
uncontrol
phase
trial
daili
dose
mg
oral
ribavirin
effect
elimin
hiv
viremia
improv
lymphoprolif
respons
limit
number
patient
studi
drug
safe
transfus
requir
patient
addit
inform
ribavirin
describ
earlier
articl
suramin
hexeth
sodium
salt
deriv
naphthalen
trisulfon
acid
antiparasit
agent
use
african
trypanosomiasi
onchocerciasi
mechan
action
pharmacokinet
suramin
found
inhibit
revers
transcript
bind
templat
primer
bind
site
dna
synthesi
revers
transcriptas
activ
reduc
drug
highli
protein
bound
halflif
day
suramin
absorb
oral
pain
administ
intramuscularli
administ
intraven
cross
bloodbrain
barrier
drug
excret
urin
toxic
rare
anaphylactoid
reaction
report
mg
test
dose
slow
intraven
infus
given
advers
reaction
common
includ
fever
skin
rash
proteinuria
elev
serum
creatinin
increas
serum
glutamicoxaloacet
transaminas
neutropenia
thrombocytopenia
adren
insuffici
paresthesia
high
frequenc
sever
side
effect
suramin
unlik
studi
unit
state
clinic
trial
three
separ
studi
aid
arc
patient
suramin
abl
suppress
hiv
viremia
effect
revers
immunolog
deficit
decreas
morbidityl
dosag
patient
receiv
mg
test
dose
intraven
g
given
intraven
week
length
therapi
undetermin
studi
unlik
miner
condens
polyanion
activ
mani
rna
dna
virus
competit
inhibit
revers
transcriptas
administ
slow
intraven
infus
short
halflif
major
toxic
hepat
thrombocytopenia
uncontrol
studi
franc
demonstr
small
decreas
viral
titer
hiv
clear
clinic
immunolog
improv
hp
appear
affect
hiv
revers
transcriptas
abil
prevent
viral
replic
doubt
spectrum
mechan
action
phosphonoform
acid
foscarnet
pf
pyrophosph
analogu
studi
agent
cmv
hepat
b
herp
simplex
viru
influenza
hiv
virus
activ
viral
dna
rna
polymeras
significantli
greater
cellular
polymeras
nousli
given
continu
short
halflif
metabol
convers
drug
rapidli
elimin
soft
tissu
excret
urin
drug
retain
bone
matrix
marrow
may
take
month
dispers
bone
bone
marrow
toxic
seen
despit
accumul
penetr
across
bloodbrain
barrier
controversi
clinic
indic
foscarnet
origin
seen
promis
agent
topic
therapi
herp
simplex
less
effect
acv
less
effect
idoxuridin
herp
kerat
use
europ
antihiv
agent
aid
arc
patient
signific
nephrotox
howev
preclud
use
unit
state
al
experiment
lipid
compound
extract
egg
yolk
inhibit
hiv
infect
name
indic
activ
lipid
al
ratio
neutral
glycerid
phosphatidylcholin
phosphatidylethanolamin
extract
cholesterol
cell
membran
therebi
weaken
viral
structur
permit
attach
viru
human
cell
vvithout
viral
attach
entri
cell
prevent
anecdot
report
reduc
level
viremia
clinic
improv
administr
al
aid
patient
major
toxic
advers
effect
describ
publish
report
experi
drug
lack
hybridon
oligonucleotid
complementari
sequenc
portion
hiv
nucleic
acid
hybridon
affect
transcript
translat
competit
inhibit
viral
rna
mrna
socal
antisens
rna
approach
clinic
experi
approach
limit
poli
ipoli
c
u
ampligen
mismatch
doublestrain
rna
molecul
appear
antihiv
well
immunomodulatori
properti
use
combin
two
drug
inhibit
differ
step
hiv
replic
cycl
studi
ideal
effect
two
drug
synergist
least
addit
need
rememb
antagonist
effect
use
two
drug
also
possibl
avoid
synerg
shown
recombin
interferon
alphaa
azt
foscarnet
ribavirin
foscarnet
antagon
shown
occur
vitro
azt
ribavirin
ribavirin
normal
increas
format
deoxythymidin
triphosph
turn
inhibit
host
cell
thymidin
kinas
tk
inhibit
thymidin
kinas
prevent
phosphoryl
azt
ddc
see
fig
newer
hiv
revers
transcriptas
inhibitor
well
nucleosid
analogu
similar
metabol
pathway
also
studi
antagon
use
combin
therapi
ddc
appear
clinic
benefit
azt
less
toxic
treat
hiv
infect
necessari
revers
immunolog
effect
viru
well
kill
sever
agent
studi
immunomodul
would
use
adjunct
therapi
antivir
drug
immunomodul
agent
studi
includ
interferon
isoprinosin
diethyldiothiocarbam
thymic
humor
factor
leukocyt
deriv
immunomodul
exampl
imreg
transfer
factor
endogen
human
cytokin
gmcsf
granulocytemacrophag
coloni
stimul
factor
naltrexon
cyclosporin
interferon
host
deriv
polypeptid
molecul
broad
spectrum
antivir
activ
well
sever
nonantivir
effect
releas
cell
respons
infect
stimuli
speciesspecif
induc
temporari
antivir
state
un
infect
cell
modul
host
immun
respons
three
class
interferon
alphainterferon
ifn
al
formerli
known
leukocyt
interferon
betainterferon
ifn
formerli
known
fibroblast
interferon
gammainterferon
ifn
formerli
known
immun
interferon
produc
lymphocyt
ifna
ifn
structur
relat
produc
respons
viral
infect
polyribonucleotid
administr
ifn
structur
differ
produc
respons
specif
antigen
stimulu
mechan
action
interferon
act
revers
bind
gangliosid
second
specif
cell
surfac
receptor
seri
intermedi
metabol
step
cytoplasm
enzym
endonucleas
oligoadenyl
synthetas
protein
kinas
activ
final
enzym
inhibit
transcript
translat
assembl
releas
viru
cell
possess
interferon
receptor
resist
drug
antivir
state
take
sever
hour
develop
may
persist
day
interferon
immunomodul
function
includ
tcell
mediat
cytotox
natur
killer
cell
activ
macrophag
function
effect
antibodi
synthesi
interferon
kill
virus
prevent
viral
reproduct
interf
nucleic
acid
protein
synthesi
advantag
agent
virusspecif
use
effect
infect
viru
identifi
cultur
serolog
pharmacokinet
interferon
administ
intravenouslv
intramuscularli
intranas
halflif
ifna
administ
intraven
hour
intramuscularli
hour
intranas
minut
ifn
penetr
well
cerebrospin
fluid
remov
hemodialysi
littl
excret
urin
metabol
unknown
unlik
ifna
ifn
must
given
intraven
obtain
therapeut
level
toxic
advers
reaction
side
effect
ifna
inject
occur
hour
administr
includ
fever
headach
malais
chill
lymphopenia
revers
cessat
therapi
mani
thought
flulik
symptom
associ
common
respiratori
infect
caus
releas
interferon
infect
cell
toxic
includ
gastrointestin
disturb
weight
loss
local
pain
fatigu
alopecia
paresthesia
confus
bone
marrc
w
suppress
hematolog
effect
dosedepend
revers
toler
develop
sever
day
intranas
use
gener
well
toler
day
use
nasal
congest
sore
throat
hoars
nasal
burn
increas
nasal
secret
mucos
friabil
bleed
crust
eros
develop
month
ifn
ex
intranas
use
submucos
inflammatori
cell
infiltr
occur
resolv
cessat
therapi
toxic
effect
seen
ifnex
ifn
appli
topic
eye
vagina
fever
fatigu
cerebrospin
fluid
pleocytosi
seen
intrathec
use
clinic
indic
antivir
use
interferon
studi
treatment
common
cold
rhinovirus
urogenit
wart
herp
simplex
virus
cmv
varicella
zoster
viru
hepat
b
papilloma
well
aid
hiv
relat
infect
studi
intranas
ifn
ex
use
decreas
rhinovirusinduc
nasal
symptom
per
cent
result
per
cent
fewer
episod
respiratori
ill
anoth
studi
treat
subject
expos
rhinoviru
per
cent
fewer
symptomat
day
per
cent
fewer
ill
placebo
group
studi
interferon
help
control
spread
cold
among
famili
prophylact
use
interferon
intranas
shown
shorten
reduc
sever
cold
symptom
challeng
coronaviru
ifn
ex
given
prophylact
subcutan
rout
suppress
recurr
genit
herp
simplex
viru
infect
decreas
number
recurr
shorter
durat
lesion
milder
symptom
benefici
effect
ifn
ex
depend
continu
administr
prodrom
begin
ifnex
effect
clinic
cours
recurr
herp
ifnex
inhibit
hiv
replic
vitroy
interferon
effect
anogenit
wart
caus
papilloma
infect
hiv
seem
reduc
therapeut
respons
anogenit
wart
drug
abnorm
level
type
ifn
aid
patient
aid
patient
ifn
inhibitori
activ
seen
arc
normal
patient
patient
arc
high
titer
ifn
serum
compar
aid
patient
high
level
ifn
may
defend
viral
agent
arc
patient
may
aid
patient
interferon
inactiv
high
interferon
level
need
good
therapeut
result
patient
kaposi
sarcoma
tissu
paper
handkerchief
impregn
virucid
compound
test
paper
treat
citric
acid
malic
acid
sodium
lauryl
sulfat
chemic
compound
virucid
rhinovirus
handtohand
transmiss
common
way
rhinovirus
spread
use
virucid
pleural
tissu
may
abl
reduc
significantli
transmiss
virus
common
caus
common
cold
experiment
antivir
agent
sever
nucleosid
analogu
investig
fiac
tiazofuror
enviroxim
nonnucleosid
agent
arildon
rifampin
zinc
among
intrigu
new
agent
studi
win
compound
win
win
test
picornavirus
especi
rhinovirus
win
compound
inhibit
uncoat
viru
penetr
host
cell
membran
canyon
groov
surfac
rhinovirus
appear
bind
site
drug
canyon
site
inaccess
host
antibodi
theoret
advantag
win
compound
clear
singl
drug
potenti
could
inhibit
rhinovirus
immun
rhinovirus
practic
altern
time
mani
viral
strain
reinfect
often
occur
presenc
antibodi
